For a while Brevo was one of the platforms peptide sellers suggested to each other after a Klaviyo ban. That changed in 2026. Brevo's acceptable use policy now lists peptide-based products among the things it won't accept, regardless of whether they're legal.
What the clause says
The clause covers peptide-based products for injectable or oral human therapeutic, weight-loss or performance use, and gives GLP-1 analogues and growth hormone peptides as examples. It explicitly includes products labeled "research use only", and applies whether or not they're sold under a prescription or legal where the recipient lives.
Archived copies of the policy page show the clause wasn't there on July 19, 2026 and was there by August 4, 2026.
What it doesn't cover
The wording is about injectable or oral use. Topical and cosmetic peptides, like those in skincare, aren't covered by this clause. If that's your category, read the full policy before you assume you're fine either way.
Why this matters beyond Brevo
Most email platforms catch peptide stores through a general rule about pharmaceutical products. Brevo naming peptides and the research-use label outright removes the gray area that let some stores argue they were selling research chemicals, not drugs. Other platforms could tighten their wording the same way.
If you're on Brevo today, export your list now while you still can. Our guide to which email platforms allow peptide brands has what every major platform's policy says, with links.